KP Tissue Inc

OTC Pink - Current Information:KPTSFUnited StatesView on Canadian Exchange

Nov 13, 2024

Show headlines and story abstract

• KP Tissue Q3 Profit Higher as Revenue Rises, from 7:55AM ET on Wednesday Nov 13, 2024 by MT Newswires

  7:55AM ET on Wednesday Nov 13, 2024 by MT Newswires
  Companies Mentioned: KPT
  07:55 AM EST, 11/13/2024 (MT Newswires) -- KP Tissue (KPT.TO) on Wednesday said third quarter-profit advanced on higher revenue. The company said net income in the quarter rose to $18 million from $12.9 million last year. Revenue rose 10% to $521.1 ...

• *DJ KP Tissue 3Q Rev C$521.1M >KPT.T, from 7:07AM ET on Wednesday Nov 13, 2024 by Dow Jones

  7:07AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: KPT

• -- KP Tissue Brief: Revenue was $521.1 million in Q3 2024; Net income was $18.0 million, from 7:01AM ET on Wednesday Nov 13, 2024 by MT Newswires

  7:01AM ET on Wednesday Nov 13, 2024 by MT Newswires
  Companies Mentioned: KPT
  07:01 AM EST, 11/13/2024 (MT Newswires) -- ...

• KP Tissue declares a Quarterly Dividend of $0.18 per Common Share, from 7:01AM ET on Wednesday Nov 13, 2024 by Dow Jones

  7:01AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: KPT
  
  KP Tissue declares a Quarterly Dividend of $0.18 per Common Share
  
  NOT FOR DISTRIBUTION IN THE U.S.A. OR OVER U.S. WIRE SERVICES
  
  MISSISSAUGA, Ontario, Nov. 13, 2024 (GLOBE NEWSWIRE) -- KP Tissue Inc. (KPT) (TSX: KPT) announced today that the Board of Directors has declared a quarterly dividend of $0.18 per common share, payable on January 15, 2025 to shareholders of record at the close of business on December 31, 2024, subject to applicable law.
  

• KP Tissue Releases Third Quarter 2024 Financial Results, from 7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones

  7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: KPT
  KP Tissue Inc. Unaudited Condensed Statements of Financial Position (thousands of Canadian dollars) September 30, 2024 December 31, 2023 $ $ ------------------ ----------------- Assets Current assets Dividends receivable 1,796 1,793 Income taxes recoverable 367 652 Receivable from Investee 65 - ------------------ ----------------- 2,228 2,445 Non-current assets Investment in associate 70,647 68,162 ------------------ ----------------- Total assets 72,875 70,607 ================== ================= Liabilities Current liabilities Dividend payable 1,796 1,793 Payable to investee - 457 Income taxes payable 376 - ----------------- Total liabilities 2,172 2,250 ------------------ ----------------- Equity Common shares 22,702 22,560 Contributed surplus 144,819 144,819 Deficit (113,398) (115,027) Accumulated other comprehensive income 16,580 16,005 ------------------ ----------------- Total equity 70,703 68,357 ------------------ ----------------- Total liabilities and equity 72,875 70,607 ================== ================= KP Tissue Inc. Unaudited Condensed Statements of Income (Loss) (thousands of Canadian dollars, except share and per share amounts) 3-month 3-month 9-month 9-month period period period period ended ended ended ended September September September September 30, 2024 30, 2023 30, 2024 30, 2023 $ $ $ $ --------- --------- --------- ---------- Share of income (loss) 2,259 1,789 4,758 (2,909) Depreciation of fair value increments (278) (286) (847) (886) Equity income (loss) 1,981 1,503 3,911 (3,795) Dilution gain 107 262 500 787 --------- --------- ---------- Income (loss) before income taxes 2,088 1,765 4,411 (3,008) --------- --------- --------- ---------- Deferred tax expense - - - 3,892 Net income (loss) 2,088 1,765 4,411 (6,900) ========= ========= ========= ========== Basic earnings (loss) per share 0.21 0.18 0.44 (0.69) ========= ========= ========= ========== Weighted average number of shares outstanding 9,979,383 9,957,841 9,973,463 9,953,646 ========= ========= ========= ========== KP Tissue Inc. Unaudited Condensed Statements of Cash Flows (thousands of Canadian dollars) 3-month 3-month 9-month 9-month period period period period ended ended ended ended September September September September 30, 2024 30, 2023 30, 2024 30, 2023 $ $ $ $ --------- --------- ---------- ---------- Cash flows from (used in) operating activities Net income (loss) 2,088 1,765 4,411 (6,900) Items not affecting cash Equity loss (income) (1,981) (1,503) (3,911) 3,795 Dilution gain (107) (262) (500) (787) Deferred tax expense - - - 3,892 Total items not affecting cash (2,088) (1,765) (4,411) 6,900 Decrease in payable to investee (376) (137) (660) (137) Tax refunds, net 376 137 660 137 Net cash from (used in) operating activities - - - - --------- --------- ---------- ---------- Cash flows from investing activities Dividends received, net 1,743 1,739 5,239 5,242 Net cash from investing activities 1,743 1,739 5,239 5,242 --------- --------- ---------- ---------- Cash flows used in financing activities Dividends paid, net (1,743) (1,739) (5,239) (5,242) --------- --------- ---------- ---------- Net cash used in financing activities (1,743) (1,739) (5,239) (5,242) --------- --------- ---------- ---------- Increase - - - - (decrease) in cash and cash equivalents during the period Cash and cash - - - - equivalents - Beginning of period --------- --------- ---------- ---------- Cash and cash - - - - equivalents - End of period ========= ========= ========== ==========